Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).

Griessbach, AlexandraAlexandraGriessbachChammartin, FrédériqueFrédériqueChammartinAbela, Irene AIrene AAbelaAmico, PatriziaPatriziaAmicoStoeckle, Marcel PMarcel PStoeckleEichenberger, AnnaAnnaEichenbergerHasse, BarbaraBarbaraHasseBraun, Dominique LDominique LBraunSchuurmans, Macé MMacé MSchuurmansMüller, Thomas FThomas FMüllerTamm, MichaelMichaelTammAudigé, AnnetteAnnetteAudigéMueller, Nicolas JNicolas JMuellerRauch, AndriAndriRauch0000-0001-5297-6062Günthard, Huldrych FHuldrych FGünthardKoller, Michael TMichael TKollerTrkola, AlexandraAlexandraTrkolaEpp, SelinaSelinaEppAmstutz, AlainAlainAmstutzSchönenberger, Christof MChristof MSchönenbergerTaji Heravi, AlaAlaTaji HeraviKusejko, KatharinaKatharinaKusejkoBucher, Heiner CHeiner CBucherBriel, MatthiasMatthiasBrielSpeich, BenjaminBenjaminSpeich2024-10-252024-10-252023-04https://boris-portal.unibe.ch/handle/20.500.12422/166376Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).enHIV Organ transplant SARS-CoV-2 Vaccine randomized trial600 - Technology::610 - Medicine & healthAntibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).article10.48350/1816173703548610.1093/ofid/ofad150